Literature DB >> 13766070

Parkinson's syndrome, depression and imipramine. A preliminary report.

A J MANDELL, C MARKHAM, W FOWLER.   

Abstract

Patients with Parkinson's syndrome whose major symptoms are akinesis, rigidity, inertia, depression, irritability and failure of adaptation rather than tremor appear to benefit in a global way from therapy with imipramine. Patients without much over-all functional impairment do not show this improvement. The hypothesis is offered that motivation to move and ability to move are perhaps neurologically as well as psychologically related functions.

Entities:  

Keywords:  DEPRESSION/therapy; PARALYSIS AGITANS/complications; PSYCHOPHARMACOLOGY

Mesh:

Substances:

Year:  1961        PMID: 13766070      PMCID: PMC1574436     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  6 in total

1.  IMIPRAMINE IN TREATMENT OF PARKINSONISM: A DOUBLE-BLIND PLACEBO STUDY.

Authors:  R R STRANG
Journal:  Br Med J       Date:  1965-07-03

2.  Effects of thymoleptics on behaviour associated with changes in brain dopamine. I. Potentiation of dopa-induced gnawing of mice.

Authors:  L Molander; A Randrup
Journal:  Psychopharmacologia       Date:  1976-02-02

Review 3.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 4.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

5.  Synergistic anticataleptic effect of imipramine and nicotine in a rotenone-induced rat model.

Authors:  Ilya D Ionov; Irina I Pushinskaya; Nicholas P Gorev; Larissa A Shpilevaya
Journal:  Psychopharmacology (Berl)       Date:  2019-05-08       Impact factor: 4.415

6.  Alterations of BDNF and trkB mRNA expression in the 6-hydroxydopamine-induced model of preclinical stages of Parkinson's disease: an influence of chronic pramipexole in rats.

Authors:  Klemencja Berghauzen-Maciejewska; Jadwiga Wardas; Barbara Kosmowska; Urszula Głowacka; Katarzyna Kuter; Krystyna Ossowska
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.